Capping Lawyers’ Tobacco Fees

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 3
Volume 7
Issue 3

WASHINGTON--One of Shakespeare’s characters wanted to "kill all the lawyers." Rep. Scott McInnis (R-Colo) just wants to cap their legal fees, at least in any national tobacco agreement. In introducing a bill to limit any legal fees from a settlement to $150 an hour plus expenses, Rep. McInnis noted that some states have entered into contracts with private attorneys that called for payments of up to 25% of funds collected from tobacco cases.

WASHINGTON--One of Shakespeare’s characters wanted to "kill all the lawyers." Rep. Scott McInnis (R-Colo) just wants to cap their legal fees, at least in any national tobacco agreement. In introducing a bill to limit any legal fees from a settlement to $150 an hour plus expenses, Rep. McInnis noted that some states have entered into contracts with private attorneys that called for payments of up to 25% of funds collected from tobacco cases.

"I hope this legislation will serve to initiate the debate regarding how the money from a tobacco settlement deal is to be allocated," he said. "I believe that the funds would best be used to prevent underage smoking, not to line the pockets of a few trial attorneys."

For example, lawyers in the recent multibillion dollar Texas settlement stand to collect $2.2 billion under their contract with the state.

Recent Videos
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
2 experts are featured in this series.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.
Two experts are featured in this series.
4 experts are featured in this series.
4 experts are featured in this series.
7 experts are featured in this series.
Combining daratumumab with other agents is one strategy that investigators are exploring in the smoldering multiple myeloma field.
Related Content